Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
Blueprint Medicines' AYVAKIT leads its revenue growth, while its pipeline targets multiple cancers. Read why BPMC stock is a ...
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...
Dr. Sanjay Gupta: Blockbuster weight loss drugs are revealing what we still don’t understand about obesity
Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...
Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria
French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
Seeking Alpha5d
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
Trading today at under $60/share, with a dividend yield of 4%, my research goal today was to explore whether ... this month ...